Treatments being tested
Clinical trials open to people with bowel cancer
Every trial here is a live record from ClinicalTrials.gov, the public registry every trial must be listed on before it starts. Statuses are re-checked against the registry every day or two, because a list that says a closed trial is recruiting is worse than no list at all.
Listing a trial is not a recommendation, and this site has no connection to any of them. Whether a trial is right for you, and whether you would be eligible, is a conversation for your own oncology team.
What these filters mean
Genotype
These are the things that make a tumour unusual, so leave them alone unless one of them is yours. Nothing selected shows every trial. Wild-type and pMMR are the ordinary results and have no button of their own: they would match almost everybody, so they would narrow nothing. Selecting a mutation drops the trials that need the ordinary result instead â which is right, because those are the ones you could not join.
Which KRAS
Only relevant if your tumour is KRAS mutated. Your report will name the exact change, such as G12C or G12D; some newer drugs are built for one specific change and no other.
Each trial is tagged by reading its own eligibility criteria automatically, to make the list searchable. The tags summarise what the criteria mention — they are not a decision about whether you qualify, and where a tag and the criteria disagree, the criteria are right.
402 trials
Recruiting nowPhase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Recruiting nowPhase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Recruiting nowPhase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Recruiting nowPhase 2
Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC
Recruiting nowPhase 1
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Recruiting nowPhase 2
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Recruiting nowPhase 2
Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme
Recruiting nowPhase 2
SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer(SPARKLE)
Recruiting nowPhase 2
A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer
Recruiting nowPhase 2
Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
Recruiting nowPhase 2
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors
Recruiting nowPhase 2
A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
Recruiting nowPhase 2
SL-28 for Advanced Solid Tumours
Recruiting nowPhase 1
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Recruiting nowPhase 2
A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma